The phosphatidylinositol 3-Kinase/mTor pathway as a therapeutic target for brain aging and neurodegeneration

Pharmaceuticals

Volumn 4, Issue 8, 2011, Pages 1070-1087

  Heras Sandoval, David ^a   Avila Muñoz, Evangelina ^a   Arias, Clorinda ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Alzheimer's disease; Brain aging; Insulin resistance; mTOR; PI3K

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AMYLOID BETA PROTEIN; INSULIN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; RAPAMYCIN; ROSIGLITAZONE; SIRTUIN; SOMATOMEDIN C; WORTMANNIN;

AGING; ALZHEIMER DISEASE; BRAIN FUNCTION; BRAIN MATURATION; CELL SURVIVAL; CLINICAL EFFECTIVENESS; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME MECHANISM; HUMAN; INSULIN RESISTANCE; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROMODULATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 80052198294     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph4081070     Document Type: Review

References (117)

1. van der Heide, L.P.; Ramakers, G.M.; Smidt, M.P. Insulin signaling in the central nervous system: Learning to survive. Prog. Neurobiol. 2006, 79, 205-221.
2. Engelman, J.A.; Luo, J.; Cantley, L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7, 606-619.
3. Hawkins, P.T.; Anderson, K.E.; Davidson, K.; Stephens, L.R. Signaling through Class I PI3Ks in mammalian cells. Biochem. Soc. Trans. 2006, 34, 647-662.
4. Arendt, T. Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: The 'Dr. Jekyll and Mr. Hyde' concept of Alzheimer's disease or the yin and yang of neuroplasticity. Prog. Neurobiol. 2003, 71, 83-248.
5. Kimura, K.D.; Tissenbaum, H.A.; Liu, Y.; Ruvkun, G. daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science 1997, 277, 942-946.
6. Brown-Borg, H.M.; Borg, K.E.; Meliska, C.J.; Bartke, A. Dwarf mice and the ageing process. Nature 1996, 384, 33-36.
7. Kapeller, R.; Cantley, L.C. Phosphatidylinositol 3-kinase. Bioessays 1994, 16, 565-576.
8. Vanhaesebroeck, B.; Waterfield, M.D. Signaling by distinct classes of phosphoinositide 3-kinases. Exp. Cell Res. 1999, 253, 239-254.
9. Shin, B.C.; Suzuki, M.; Inukai, K.; Anai, M.; Asano, T.; Takata, K. Multiple isoforms of the regulatory subunit for phosphatidylinositol 3-kinase (PI3-kinase) are expressed in neurons in the rat brain. Biochem. Biophys. Res. Commun. 1998, 246, 313-319.
10. Trejo, J.L.; Pons, S. Phosphatidylinositol-3-OH kinase regulatory subunits are differentially expressed during development of the rat cerebellum. J. Neurobiol. 2001, 47, 39-50.
11. Rodgers, E.E.; Theibert, A.B. Functions of PI 3-kinase in development of the nervous system. Int. J. Dev. Neurosci. 2002, 20, 187-197.
12. Peltier, J.; O'Neill, A.; Schaffer, D.V. PI3K/AKT and CREB regulate adult neural hippocampal progenitor proliferation and differentiation. Dev. Neurobiol. 2007, 67, 1348-1361.
13. Akiyama, H.; Kamiguchi, H. Phosphatidylinositol 3-kinase facilitates microtubule-dependent membrane transport for neuronal growth cone guidance. Biol. Chem. 2010, 285, 41740-41748.
14. Bruel-Jungerman, E.; Veyrac, A.; Dufour, F.; Horwood, J.; Laroche, S.; Davis, S.; Davis, S.; Manzoni, O.J. Inhibition of PI3K-AKT signaling blocks exercise-mediated enhancement of adult neurogenesis and synaptic plasticity in the dentate gyrus. PLoS ONE 2009, 4, e7901.
15. Horwood, J.M.; Dufour, F.; Laroche, S.; Davis, S. Signaling mechanisms mediated by the phosphoinositide 3-kinase/AKT cascade in synaptic plasticity and memory in the rat. Eur. J. Neurosci. 2006, 23, 3375-3384.
16. Sui, L.; Wang, J.; Li, B.M. Role of the phosphoinositide 3-kinase-AKT-mammalian target of the rapamycin signaling pathway in long-term potentiation and trace fear conditioning memory in rat medial prefrontal cortex. Learn. Mem. 2008, 15, 762-776.
17. Hoyer, S. The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. J. Neural Transm. 2002, 109, 991-1002.
18. Zhao, W.; Chen, H.; Xu, H.; Moore, E.; Meiri, N.; Quon, M.J.; Alkon, D.L. Brain insulin receptors and spatial memory. J. Biol. Chem. 1999, 274, 34893-34902.
19. Wang, Q.; Liu, L.; Pei, L.; Ju, W.; Ahmadian, G.; Lu, J.; Wang, Y.; Liu, F.; Wang, Y.T. Control of synaptic strength, a novel function of AKT. Neuron 2003, 38, 915-928.
20. Je, H.S.; Ji, Y.; Wang, Y.; Yang, F.; Wu, W.; Lu, B. Presynaptic protein synthesis required for NT-3-induced long-term synaptic modulation. Mol. Brain 2011, 4, 1-8.
21. Je, H.S.; Lu, Y.; Yang, F.; Nagappan, G.; Zhou, J.; Jiang, Z.; Nakazawa, K.; Lu, B. Chemically inducible inactivation of protein synthesis in genetically targeted neurons. J. Neurosci. 2009, 29, 6761-6766.
22. Blagosklonny, M.V. Aging and immortality: Quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle 2006, 5, 2087-2102.
23. Liang, H.; Masoro, E.J.; Nelson, J.F.; Strong, R.; McMahan, C.A.; Richardson, A. Genetic mouse models of extended lifespan. Exp. Gerontol. 2003, 38, 1353-1364.
24. Bartke, A.; Brown-Borg, H.; Mattison, J.; Kinney, B.; Hauck, S.; Wright, C. Prolonged longevity of hypopituitary dwarf mice. Exp. Gerontol. 2001, 36, 21-28.
25. Haigis, M.C.; Yankner, B.A. The aging stress response. Mol. Cell 2010, 40, 280-293.
26. Kenyon, C.J. The genetics of aging. Nature 2010, 464, 504-512.
27. Tang, B.L. Sirt1's systemic protective roles and its promise as a target in antiaging medicine. Transl. Res. 2011, 157, 276-284.
28. Collado, M.; Medema, R.H.; Garcia-Cao, I.; Dubuisson, M.L.; Barradas, M.; Glassford, J.; Rivas, C.; Burgering, B.M.; Serrano, M.; Lam, E.W. Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J. Biol. Chem. 2000, 275, 21960-21968.
29. Kenyon, C. The plasticity of aging: Insights from long-lived mutants. Cell 2005, 120, 449-460.
30. Morris, J.Z.; Tissenbaum, H.A.; Ruvkun, G. A phosphatidylinositol-3-OH kinase family member regulating longevity and diapause in Caenorhabditis elegans. Nature 1996, 382, 536-539.
31. Clancy, D.J.; Gems, D.; Harshman, L.G.; Oldham, S.; Stocker, H.; Hafen, E.; Leevers, S.J.; Partridge, L. Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein. Science 2001, 292,104-106.
32. Taguchi, A.; Wartschow, L.M.; White, M.F. Brain IRS2 signaling coordinate life span and nutrient homeostasis. Science 2007, 317, 369-372.
33. Bartke, A. Role of the growth hormone/insulin-like growth factor system in mammalian aging. Endocrinology 2005, 146, 3718-3723.
34. Barbieri, M.; Gambardella, A.; Paolisso, G.; Varricchio, M. Metabolic aspects of the extreme longevity. Exp. Gerontol. 2008, 43, 74-78.
35. Rozing, M.P.; Westendorp, R.G.; Frölich, M.; de Craen, A.J.; Beerkman, M.; Heijmans, B.T.; Mooijaart, S.P.; Blauw, G.J.; Slagboom, P.E.; van Heemst, D. Human insulin/IGF-1 and familial longevity at middle age. Aging 2009, 1, 714-722.
36. Bonkowski, M.S.; Rocha, J.S.; Masternak, M.M.; Al Regaiey, K.A.; Bartke, A. Targeted disruption of growth hormone receptor interferes with the beneficial actions of calorie restriction. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 7901-7905.
37. Tsang, C.K.; Qi, H.; Liu, L.F.; Zheng, X.F. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov. Today 2007, 12, 112-124.
38. Arsham, A.M.; Neufeld, T.P. Thinking globally and acting locally with TOR. Curr. Opin. Cell Biol. 2006, 18, 589-597.
39. Sharp, Z.D.; Bartke, A. Evidence for down-regulation of phosphoinositide 3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR)-dependent translation regulatory signaling pathways in Ames dwarf mice. J. Gerontol. A Biol. Sci. Med. Sci. 2005, 60, 293-300.
40. Wullschleger, S.; Loewith, R.; Hall, M.N. TOR signaling in growth and metabolism. Cell 2006, 124, 471-484.
41. Cuervo, A.M. Autophagy: Many paths to the same end. Mol. Cell Biochem. 2004, 263, 55-72.
42. Kelly, G.S. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: Part 1. Altern. Med. Rev. 2010, 15, 245-263.
43. Fröjdö, S.; Durand, C.; Molin, L.; Carey, A.L.; El-Osta, A.; Kingwellg, B.A.; Febbraio, M.A.; Solari, F.; Vidal, H.; Pirola, L. Phosphoinositide 3-kinase as a novel functional target for the regulation of the insulin signaling pathway by SIRT1. Mol. Cell Endocrinol. 2011, 335, 166-176.
44. Kelly, G.S. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: Part 2. Altern. Med. Rev. 2010, 15, 313-328.
45. Xiong, S.; Salazar, G.; Patrushev, N.; Alexander, R.W. FoxO1 mediates an autofeedback loop regulating SIRT1 expression. J. Biol. Chem. 2011, 286, 5289-5299.
46. Butterfield, D.A.; Howard, B.; Yatin, S.; Koppal, T.; Drake, J.; Hensley, K.; Aksenov, M.; Aksenova, M.; Subramaniam, R.; Varadarajan, S.; et al. Elevated oxidative stress in models of normal brain aging and Alzheimer's disease. Life Sci. 1999, 65, 1883-1892.
47. Mattson, M.P. Calcium and neurodegeneration. Aging Cell 2007, 6, 337-350.
48. Sastre, J.; Pallardó, F.V.; Viña, J. The role of mitochondrial oxidative stress in aging. Free Radic. Biol. Med. 2003, 35, 1-8.
49. Sloane, J.A.; Hollander, W.; Moss, M.B.; Rosene, D.L.; Abraham, C.R. Increased microglial activation and protein nitration in white matter of the aging monkey. Neurobiol. Aging 1999, 20, 395-405.
50. Fubini, B.; Hubbard, A. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis. Free Radic. Biol. Med. 2003, 34, 1507-1516.
51. Golden, T.R.; Hinerfeld, D.A.; Melov, S. Oxidative stress and aging: Beyond correlation. Aging Cell 2010, 1, 117-123.
52. Papadia, S.; Soriano, F.X.; Léveillé, F.; Martel, M.A.; Dakin, K.A.; Hansen, H.H.; Kaindl, A.; Sifringer, M.; Fowler, J.; Stefovska, V.; et al. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat. Neurosci. 2008, 11, 476-487.
53. Galasko, D.; Montine, T. Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark. Med. 2010, 4, 27-36.
54. Datta, S.R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M.E. AKT phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91, 231-241.
55. Owada, Y.; Utsunomiya, A.; Yoshimoto, T.; Kondo, H. Expression of mRNA for AKT, serine-threonine protein kinase, in the brain during development and its transient enhancement following axotomy of hypoglossal nerve. J. Mol. Neurosci. 1997, 9, 27-33.
56. Chong, Z.Z.; Kang, J.Q.; Maiese, K. AKT1 drives endothelial cell membrane asymmetry and microglial activation through Bcl-x(L) and caspases 1, 3, and 9. Exp. Cell Res. 2004, 296, 196-207.
57. Kang, J.Q.; Chong, Z.Z.; Maiese, K. Critical role for AKT1 in the modulation of apoptotic phosphatidylserine exposure and microglial activation. Mol. Pharmacol. 2003, 64, 557-569.
58. Crowder, R.J.; Freeman, R.S. Phosphatidylinositol 3-kinase and AKT protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons. J. Neurosci. 1998, 18, 2933-2943.
59. Kang, J.Q.; Chong, Z.Z.; Maiese, K. AKT1 protects against inflammatory microglial activation through maintenance of membrane asymmetry and modulation of cysteine protease activity. J. Neurosci. Res. 2003, 74, 37-51.
60. Murata, H.; Sakaguchi, M.; Jin, Y.; Sakaguchi, Y.; Futami, J.; Yamada, H.; Kataoka, K.; Huh, N.H. A new cytosolic pathway from a Parkinson disease-associated kinase, BRPK/PINK1: activation of AKT via mTORC2. J. Biol. Chem. 2011, 286, 7182-7189.
61. Lu, J.; Wu, D.M.; Zheng, Z.H.; Zheng, Y.L.; Hu, B.; Zhang, Z.F. Troxerutin protects against high cholesterol-induced cognitive deficits in mice. Brain 2011, 134, 783-797.
62. Schieke, S.M.; Phillips, D.; McCoy, J.P.; Aponte, A.M.; Shen, R.F.; Balaban, R.S.; Finkel, T. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J. Biol. Chem. 2006, 281, 27643-27652.
63. Selkoe, D.J. Aging, amyloid, and Alzheimer's disease: A perspective in honor of Carl Cotman. Neurochem. Res. 2003, 28, 1705-1713.
64. Haugabook, S.J.; Le, T.; Yager, D.; Zenk, B.; Healy, B.M.; Eckman, E.A.; Prada, C.; Younkin, L.; Murphy, P.; Pinnix, I.; et al. Reduction of Aß accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidylinositol kinase inhibitor wortmannin. FASEB J. 2000, 15, 16-18.
65. Solano, D.C.; Sironi, M.; Bonfini, C.; Solerte, S.B.; Govoni, S.; Racchi, M. Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB J. 2000, 14, 1015-1022.
66. Gasparini, L.; Gouras, G.K.; Wang, R.; Gross, R.S.; Beal, M.F.; Greengard, P.; Xu, H. Stimulation of beta amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 2001, 21, 2561-2570.
67. Costantini, C.; Scrable, H.; Puglielli, L. An aging pathway controls the TrkA to p75NTR receptor switch and amyloid beta-peptide generation. EMBO J. 2006, 25, 1997-2006.
68. Maesako, M.; Uemura, K.; Kubota, M.; Ando, K.; Kuzuya, A.; Asada, M.; Kihara, T.; Kinoshita, A. Insulin regulates Presenilin 1 localization via PI3K/AKT signaling. Neurosci. Lett. 2010, 483, 157-161.
69. Ksiezak-Reding, H.; Pyo, H.K.; Feinstein, B.; Pasinetti, G.M. AKT/PKB kinase phosphorylates separately Thr212 and Ser214 of tau protein in vitro. Biochim. Biophys. Acta 2003, 1639, 159-168.
70. Yanagisawa, M.; Planel, E.; Ishiguro, K.; Fujita, S.C. Starvation induces tau hyperphosphorylation in mouse brain: Implications for Alzheimer's disease. FEBS Lett. 1999, 461, 329-333.
71. Okawa, Y.; Ishiguro, K.; Fujita, S.C. Stress-induced hyperphosphorylation of tau in the mouse brain. FEBS Lett. 2003, 535, 183-189.
72. Hernández, F.; de Barreda, E.G.; Fuster-Matanzo, A.; Goñi-Oliver, P.; Lucas, J.J.; Ávila, J. The role of GSK3 in Alzheimer disease. Brain Res. Bull. 2009, 80, 248-250.
73. Lee, H.-K.; Kumar, P.; Fu, Q.; Rosen, K.M.; Querfurth, H.W. The insulin/AKT signaling pathway is targeted by intracellular ß-amyloid. Mol. Biol. Cell 2009, 20, 1533-1544.
74. Umegaki, H. Pathophysiology of cognitive dysfunction in older people with type 2 diabetes: Vascular changes or neurodegeneration? Age Ageing. 2010, 39, 8-10.
75. Schrijvers, E.M.; Witteman, J.C.; Sijbrands, E.J.; Hofman, A.; Koudstaal, P.J.; Breteler, M.M. Insulin metabolism and the risk of Alzheimer disease: The Rotterdam study. Neurology 2010, 75, 1982-1987.
76. Sima, A.A. Encephalopathies: The emerging diabetic complications. Acta Diabetol. 2010, 47, 279-293.
77. Matsuzaki, T.; Sasaki, K.; Tanizaki, Y.; Hata, J.; Fujimi, K.; Matsui, Y.; Sekita, A.; Suzuki, S.O.; Kanba, S.; Kiyohara, Y.; et al. Insulin resistance is associated with the pathology of Alzheimer disease: The Hisayama study. Neurology 2010, 75, 764-770.
78. Meigs, J.B. Invited commentary: Insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am. J. Epidemiol. 2000, 152, 908-911.
79. Whitmer, R.A.; Gunderson, E.P.; Barrett-Connor, E.; Quesenberry, C.P., Jr.; Yaffe, K. Obesity in middle age and future risk of dementia: A 27 year longitudinal population based study. Br. Med. J. 2005, 330, 1360.
80. Li, L.; Hlscher, C. Common pathological processes in Alzheimer disease and type 2 diabetes: A review. Brain Res. Rev. 2007, 56, 384-402.
81. Frolich, L.; Blum-Degen, D.; Bernstein, H.G.; Engelsberger, S.; Humrich, J.; Laufer, S.; Muschner, D.; Thalheimer, A.; Turk, A.; Hoyer, S.; et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J. Neural Transm. 1998, 105, 423-438.
82. Hoyer, S. Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J. Neural Transm. 1998, 105, 415-422.
83. Gispen, W.H.; Biessels, G.J. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci. 2000, 23, 542-549.
84. Biessels, G.J.; Kappelle, L.J. Increased risk of Alzheimer's disease in Type II diabetes: Insulin resistance of the brain or insulin-induced amyloid pathology? Biochem. Soc. Trans. 2005, 33, 1041-1044.
85. Yamagishi, S.I. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp. Gerontol. 2010, 46, 217-224.
86. Partridge, L.; Gems, D. Beyond the evolutionary theory of ageing, from functional genomics to evo-gero. Trends Ecol. Evol. 2006, 21, 334-340.
87. Issad, T. O-GlcNAc glycosylation and regulation of cell signaling. Med. Sci. 2010, 26, 753-759.
88. Deng, Y.; Li, B.; Liu, Y.; Iqbal, K.; Grundke-Iqbal, I.; Gong, C.X. Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. Am. J. Pathol. 2009, 175, 2089-2098.
89. Manolopoulos, K.N.; Klotz, L.O.; Korsten, P.; Bornstein, S.R.; Barthel A. Linking Alzheimer's disease to insulin resistance: The FoxO response to oxidative stress. Mol. Psychiatry 2010, 15, 1046-1052.
90. Zhao, W.Q.; Lacor, P.N.; Chen, H.; Lambert, M.P.; Quon, M.J.; Krafft, G.A.; Klein, W.L. Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric Aß. J. Biol. Chem. 2009, 284, 18742-18753.
91. Freude, S.; Plum, L.; Schnitker, J.; Leeser, U.; Udelhoven, M.; Krone, W.; Bruning, J.C.; Schubert, M. Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes 2005, 54, 3343-3348.
92. Maesako, M.; Uemura, K.; Kubota, M.; Ando, K.; Kuzuya, A.; Asada, M.; Kihara, T.; Kinoshita, A. Insulin regulates Presenilin 1 localization via PI3K/AKT signaling. Neurosci. Lett. 2010, 483, 157-161.
93. Bhaskar, K.; Miller, M.; Chludzinski, A.; Herrup, K.; Zagorski, M.; Lamb, B.T. The PI3K-AKT-mTOR pathway regulates Aß oligomer induced neuronal cell cycle events. Mol. Neurodegener. 2009, 4, 14.
94. Schubert, M.; Gautam, D.; Surjo, D.; Ueki, K.; Baudler, S.; Schubert, D.; Kondo, T.; Alber, J.; Galldiks, N.; Kustermann, E.; et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 3100-3105.
95. Liu, Y.; Liu, F.; Grundke-Iqbal, I.; Iqbal, K.; Gong, C.X. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J. Pathol. 2011, 225, 54-62.
96. McClean, P.L.; Parthasarathy, V.; Favire, E.; Hölscher, C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 2011, 31, 6587-6594.
97. Szkudelski, T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol. Res. 2001, 50, 537-546.
98. Planel, E.; Tatebayashi, Y.; Miyasaka, T.; Liu, L.; Wang, L.; Herman, M.; Yu, W.H.; Luchsinger, J.A.; Wadzinski, B.; Duff, K.E.; et al. Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J. Neurosci. 2007, 27, 13635-13648.
99. Jolivalt, C.G.; Lee, C.A.; Beiswenger, K.K.; Smith, J.L.; Orlov, M.; Torrance, M.A.; Masliah, E. Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: Parallels with Alzheimer's disease and correction by insulin. J. Neurosci. Res. 2008, 86, 3265-3274.
100. Kim, B.; Backus, C.; Oh, S.; Hayes, J.M.; Feldman, E.L. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 2009, 150, 5294-5301.
101. Park, S.A. A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: Evidence from animal models. J. Clin. Neurol. 2011, 7, 10-18.
102. Grunblatt, E.; Salkovic-Petrisic, M.; Osmanovic, J.; Riederer, P.; Hoyer, S. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J. Neurochem. 2007, 101, 757-770.
103. Plaschke, K.; Kopitz, J.; Siegelin, M.; Schliebs, R.; salkovic-Petrisic, M.; Riederer, P.; Hoyer, S. Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AßPP-overexpressing mice. J. Alzheimer's Dis. 2010, 19, 691-704.
104. Lenzen, S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 2008, 51, 216-226.
105. McEwen, B.S.; Reagan, L.P. Glucose transporter expression in the central nervous system: Relationship to synaptic function. Eur. J. Pharmacol. 2004, 490, 13-24.
106. Terwel, D.; Prickaerts, J.; Meng, F.; Jolles, J. Brain enzyme activities after intracerebroventricular injection of streptozotocin in rats receiving acetyl-L-carnitine. Eur. J. Pharmacol. 1995, 287, 65-71.
107. Shoham, S.; Bejar, C.; Kovalev, E.; Weinstock, M. Intracerebroventricular injection of streptozotocin causes neurotoxicity to myelin that contributes to spatial memory deficits in rats. Exp. Neurol. 2003, 184, 1043-1052.
108. Gabelli, S.B.; Mandelker, D.; Schmidt-Kittler, O.; Vogelstein, B.; Amzel, L.M. Somatic mutations in PI3Kalpha: Structural basis for enzyme activation and drug design. Biochim. Biophys. Acta 2010, 1804, 533-540.
109. Aoyagi, N.; Uemura, K.; Kuzuya, A.; Kihara, T.; Kawamata, J.; Shimohama, S.; Kinoshita, A.; Takahashi, R. PI3K inhibition causes the accumulation of ubiquitinated presenilin 1 without affecting the proteasome activity. Biochem. Biophys. Res. Commun. 2010, 391, 1240-1245.
110. Risner, M.E.; Saunders, A.M.; Altman, J.F.; Ormandy, G.C.; Craft, S.; Foley, I.M.; Zvartau-Hind, M.E.; Hosford, D.A.; Roses, A.D. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006, 4, 246-254.
111. Blagosklonny, M.V. Aging ROS or TOR. Cell Cycle 2008, 7, 3344-3354.
112. Wang, X.; Proud, C.G. The mTOR pathway in the control of protein synthesis. Physiology 2006, 21, 362-369.
113. Harrison, D.E.; Strong, R.; Sharp, Z.D.; Nelson, J.F.; Astle, C.M.; Flurkey, K.; Nadon, N.L.; Wilkinson, J.E.; Frenkel, K.; Carter, C.S.; et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460, 392-395.
114. Thoreen, C.C.; Kang, S.A.; Chang, J.W.; Liu, Q.; Zhang, J.; Gao, Y.; Reichling, L.J.; Sim, T.; Sabatini, D.M.; Gray, N.S. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 2009, 284, 8023-8032.
115. Chresta, C.M.; Davies, B.R.; Hickson, I.; Harding, T.; Cosulich, S.; Critchlow, S.E.; Vincent, J.P.; Ellston, R.; Jones, D.; Sini, P.; et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010, 70, 288-298.
116. Zoncu, R.; Efeyan, A.; Sabatini, D.M. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12, 21-35.
117. Fan, Q.W.; Knight, Z.A.; Goldenberg, D.D.; Yu, W.; Mostov, K.E.; Stokoe, D.; Shokat, K.M.; Weiss, W.A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006, 9, 341-349.